Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

By LabMedica International staff writers
Posted on 10 Sep 2025

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. More...

Traditional systems for isolating circulating tumor cells (CTCs) vary in efficiency and are limited by size or marker-based restrictions. Now, a new approach has demonstrated the ability to isolate not only tumor cells but also cancer-associated fibroblasts, significantly enhancing diagnostic accuracy and treatment monitoring.

Researchers at the Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, South Korea), along with collaborators, have developed an automated platform known as CTCeptor. Unlike existing FDA-approved systems that rely on markers or size-based methods, this hemocyte extraction–based technology captures tumor cells of different sizes and markers. Importantly, it can also isolate cancer-associated fibroblasts (cCAFs), which are critical players in the tumor microenvironment.

The study compared three FDA-approved automated CTC isolation systems (marker-based, size-based, and hemocyte extraction–based) based on the same blood samples of early-stage breast cancer patients. Their comparison of CTCeptor with CellSearch and Parsortix showed that CTCeptor detected at least 15 times more CTCs than competing technologies and identified cCAFs at a frequency about 10 times higher than tumor cells. The findings, published in Analytical Chemistry, also demonstrated stable recovery rates across breast, lung, and ovarian cancer cell lines, regardless of EpCAM expression or cell size.

By capturing both CTCs and fibroblasts, CTCeptor offers a more comprehensive picture of the tumor microenvironment. This could improve early cancer diagnosis, refine treatment monitoring, and enhance the success rate of drug development. The ability to analyze tumor and microenvironment cells from a single blood sample makes this technology a powerful tool for advancing precision oncology and personalizing treatment strategies.

“Although liquid biopsy technology has focused on obtaining cancer information from blood for the past 25 years, this study holds significance, as it serves as the basis for identifying not only cancer but also key information about the tumor microenvironment,” said DGIST Professor Minseok Kim, lead author of the study. “Our technology can simultaneously analyze tumor cells and microenvironment cells with a single blood sample, which will greatly contribute to increasing the success rate of new drug development and establishing personalized treatment strategies.”

Related Links:
DGIST


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
Alcohol Testing Device
Dräger Alcotest 7000
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.